One in Four Americans at Risk for Steatotic Liver Disease But Many Remain Undiagnosed

American Liver Foundation Launches Think Liver Think Life^® campaign to Screen Nationwide

The rise in obesity and diabetes in the United States is fueling a little understood yet life-threatening disease known as steatotic liver disease*, which affects an estimated 80-100 million people, many of whom are unaware they even have it. Steatotic liver disease used to be called fatty liver disease. In its most severe form, steatotic liver disease can progress to liver failure. To address this growing problem American Liver Foundation has announced a nationwide screening and public awareness campaign, Think Liver Think Life, launching this summer to test at-risk children and adults in all 50 states over the next five years.

“We absolutely have to address this looming public health crisis and Think Liver Think Life will play a significant role in helping us do just that,” said Lorraine Stiehl, Chief Executive Officer, American Liver Foundation. “A team of ALF’s health specialists will partner with local community health centers and state departments of health to screen those most at risk for steatotic liver disease and provide a connection to follow-up care where appropriate. Getting a diagnosis early is critical because it gives patients a chance to reverse course before liver disease progresses.”

Those most at risk for metabolic dysfunction-associated steatotic liver disease (MALSD)*, previously called nonalcoholic fatty liver disease (NAFLD), include people with type 2 diabetes, high BMI or obesity, and Hispanic and Asian communities. MASLD is one of the most common causes of liver disease in the U.S. and the most common cause of liver disease worldwide, affecting as many as one billion people. It is the most common form of liver disease in children and has more than doubled over the past 20 years. MASLD causes excess fat to build up in the liver, has few or no symptoms and its exact causes are still being studied though research points to genetics, digestive disorders, and diet. It is not caused by heavy alcohol use (alcohol-associated liver disease).

Metabolic dysfunction-associated steatohepatitis* (MASH), previously called nonalcoholic steatohepatitis or NASH, is a form of MASLD causing inflammation of the liver and liver damage, which can lead to liver failure.

Think Liver Think Life aims to help prevent and detect liver disease earlier, affect better management and treatment of liver disease, reduce stigma associated with liver disease, address health inequalities, advance changes in federal policy and increase funding for research. The campaign launches in ten states this summer with diagnostic testing including liver panels, viral hepatitis antibody screening, and assessments to help identify MASLD/MASH and liver cancer. It also includes a public awareness campaign, patient and provider education, and a resource and information center all kicking off in October 2022.

“The potential impact of Think Liver Think Life is enormous,” said Tamar Taddei, MD, ALF National Medical Advisor and Professor of Medicine, Yale School of Medicine. “Early screening and diagnosis will not only help reduce the long-term effects of fatty liver disease but reduce costs associated with treating the disease over a patient’s lifetime.” It is estimated that the United States will spend $175 billion to treat patients with MASH over the next two decades.

The initial ten states with screenings this summer are: Alabama, Arizona, Florida, Kentucky, New Mexico, New York, Ohio, Pennsylvania, Texas and West Virginia adding ten states each year over the next five years.

*Steatotic liver disease used to be known as fatty liver disease..

*Metabolic dysfunction-associated liver disease (MASLD) used to be known as nonalcoholic fatty liver disease (NAFLD).

*Metabolic dysfunction-associated steatohepatitis (MASH) hused to be known as nonalcoholic steatohepatitis (NASH).

Medically reviewed on April 2025.

Last updated on June 5th, 2025 at 04:15 pm